No Data
No Data
Express News | Ensysce Biosciences Announce SInterim Data From Second Trial Evaluating PF614-MPAR Showing A 100mg Dosage Form Provided Overdose Protection
Ensysce Biosciences Regains Compliance With Nasdaq
Ensysce Biosciences Regains Full Nasdaq Compliance
Ensysce Biosciences Regains Full Compliance With Nasdaq
Express News | Ensysce Biosciences Secures Commercial Supplier For PF614-MPAR Overdose Protection Drug, Fully Establishing Supply Chain With GMP Nafamostat From Aurore Life Sciences
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Unlock the Full List